[go: up one dir, main page]

AR077454A1 - Preparaciones insulinicas que comprenden metionina - Google Patents

Preparaciones insulinicas que comprenden metionina

Info

Publication number
AR077454A1
AR077454A1 ARP100102418A ARP100102418A AR077454A1 AR 077454 A1 AR077454 A1 AR 077454A1 AR P100102418 A ARP100102418 A AR P100102418A AR P100102418 A ARP100102418 A AR P100102418A AR 077454 A1 AR077454 A1 AR 077454A1
Authority
AR
Argentina
Prior art keywords
insulin
pharmaceutical formulation
formulation according
metionin
insulinic
Prior art date
Application number
ARP100102418A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR077454A1 publication Critical patent/AR077454A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)

Abstract

La presente se refiere a una formulacion farmacéutica acuosa con insulina, análogo de insulina o derivado de insulina, y metionina; y también a su preparacion, al uso para tratar diabetes mellitus, y a un medicamento para tratar diabetes mellitus. Reivindicacion 2: La formulacion farmacéutica de acuerdo con la reivindicacion 1, estando seleccionada la insulina de un grupo que contiene insulina humana, insulina porcina e insulina bovina. Reivindicacion 8: La formulacion farmacéutica de acuerdo con una o varias de las reivindicaciones 1 a 7, que comprende 0,001 a 0,5 mg/ml de zinc, 0,1 a 5,0 mg/ml de un conservante y 5,0 a 100 mg/ml de un agente isotonico y que tiene un pH de menos de 5. Reivindicacion 20: La formulacion farmacéutica de acuerdo con una o varias de las reivindicaciones 1 a 12, que también comprende un péptido-1 tipo glucagon (GLP1) o uno de sus análogos o derivados, o exendina-3 y/o -4 o uno de sus análogos o derivados.
ARP100102418A 2009-07-06 2010-07-06 Preparaciones insulinicas que comprenden metionina AR077454A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009031748 2009-07-06
DE102010013134 2010-03-27

Publications (1)

Publication Number Publication Date
AR077454A1 true AR077454A1 (es) 2011-08-31

Family

ID=43429596

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102418A AR077454A1 (es) 2009-07-06 2010-07-06 Preparaciones insulinicas que comprenden metionina

Country Status (32)

Country Link
US (2) US20120252724A1 (es)
EP (2) EP3202394A1 (es)
JP (1) JP5735960B2 (es)
KR (2) KR101853606B1 (es)
CN (4) CN107080836A (es)
AR (1) AR077454A1 (es)
AU (1) AU2010270325B2 (es)
BR (1) BR112012000177B1 (es)
CA (2) CA2980198C (es)
CL (1) CL2012000026A1 (es)
CO (1) CO6480996A2 (es)
CY (1) CY1119582T1 (es)
DK (1) DK2451437T3 (es)
ES (1) ES2614161T3 (es)
HR (1) HRP20170155T1 (es)
HU (1) HUE030499T2 (es)
IL (2) IL217327A (es)
LT (1) LT2451437T (es)
MA (1) MA33442B1 (es)
MX (1) MX2012000304A (es)
MY (1) MY159865A (es)
NZ (1) NZ597757A (es)
PH (2) PH12011502708B1 (es)
PL (1) PL2451437T3 (es)
PT (1) PT2451437T (es)
RU (1) RU2540485C2 (es)
SG (2) SG177567A1 (es)
SI (1) SI2451437T1 (es)
TW (1) TWI520745B (es)
UY (1) UY32764A (es)
WO (1) WO2011003822A2 (es)
ZA (1) ZA201200195B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2229407T3 (en) 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
TW201113032A (en) * 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
AU2010317995B2 (en) * 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN105797140B (zh) * 2011-06-17 2020-08-11 哈洛齐梅公司 乙酰透明质酸降解酶的稳定制剂
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN112266414A (zh) * 2012-11-05 2021-01-26 卡斯西部储备大学 长效单链胰岛素类似物
CN104994864B (zh) 2012-12-19 2018-05-29 沃克哈特有限公司 包含人胰岛素或其类似物或衍生物的稳定水性组合物
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
AR098168A1 (es) * 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN117337299A (zh) * 2021-05-03 2024-01-02 印地安纳大学理事会 葡萄糖响应性胰岛素类似物葡萄糖传感器的分子设计

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033474B2 (ja) * 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
DE69939900D1 (de) * 1998-06-05 2008-12-24 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CN1245216C (zh) * 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
US6852694B2 (en) * 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1572892A4 (en) * 2001-10-18 2007-08-22 Bristol Myers Squibb Co HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
CN1607958A (zh) * 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US7763582B2 (en) * 2006-02-21 2010-07-27 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
NZ580447A (en) * 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
ES2393233T3 (es) * 2007-11-01 2012-12-19 Merck Serono S.A. Formulaciones de LH líquidas
DK2229407T3 (en) * 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CN103736082A (zh) * 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
TW201113032A (en) * 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
CN102711804B (zh) * 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) * 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins

Also Published As

Publication number Publication date
KR101853606B1 (ko) 2018-05-03
TWI520745B (zh) 2016-02-11
EP2451437A2 (de) 2012-05-16
BR112012000177B1 (pt) 2021-06-01
TW201113031A (en) 2011-04-16
IL244941A0 (en) 2016-05-31
SG10201403840VA (en) 2014-10-30
WO2011003822A2 (de) 2011-01-13
CN105535943A (zh) 2016-05-04
UY32764A (es) 2011-01-31
CN103690958A (zh) 2014-04-02
ZA201200195B (en) 2012-09-26
CY1119582T1 (el) 2018-03-07
US20250255803A1 (en) 2025-08-14
LT2451437T (lt) 2017-02-27
KR20120089442A (ko) 2012-08-10
KR20160036106A (ko) 2016-04-01
MX2012000304A (es) 2012-01-27
CN107080836A (zh) 2017-08-22
SG177567A1 (en) 2012-02-28
CA2980198A1 (en) 2011-01-13
CA2980198C (en) 2019-04-30
BR112012000177A2 (pt) 2020-08-11
SI2451437T1 (sl) 2017-03-31
DK2451437T3 (en) 2017-02-13
CA2767251C (en) 2018-08-21
PH12016500606A1 (en) 2016-11-28
RU2012103901A (ru) 2013-08-20
AU2010270325B2 (en) 2014-06-19
CA2767251A1 (en) 2011-01-13
WO2011003822A3 (de) 2011-08-25
EP2451437B1 (de) 2016-11-02
EP3202394A1 (de) 2017-08-09
JP2012532178A (ja) 2012-12-13
KR101852328B1 (ko) 2018-04-26
IL217327A (en) 2017-09-28
RU2540485C2 (ru) 2015-02-10
JP5735960B2 (ja) 2015-06-17
MA33442B1 (fr) 2012-07-03
ES2614161T3 (es) 2017-05-29
NZ597757A (en) 2014-06-27
PH12011502708A1 (en) 2012-11-12
CN102596175A (zh) 2012-07-18
HRP20170155T1 (hr) 2017-03-24
HUE030499T2 (hu) 2017-05-29
US20120252724A1 (en) 2012-10-04
IL217327A0 (en) 2012-02-29
MY159865A (en) 2017-02-15
PL2451437T3 (pl) 2017-05-31
IL244941A (en) 2017-12-31
AU2010270325A1 (en) 2012-02-16
PH12011502708B1 (en) 2017-11-10
CL2012000026A1 (es) 2012-10-05
CO6480996A2 (es) 2012-07-16
PT2451437T (pt) 2017-01-17

Similar Documents

Publication Publication Date Title
AR077454A1 (es) Preparaciones insulinicas que comprenden metionina
AR081200A1 (es) Formulaciones de insulina de accion prolongada
AR077455A1 (es) Preparaciones insulinicas de accion lenta
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
CL2012001232A1 (es) Composicion farmaceutica liquida que comprende un agonista de glp-1: despro36 exendina-4-(1-39)-lys6-nh2, insulina humana gly(a21)-arg(b31)-arg(b32), o sales de ellos, l-metionina y opcionalmente un excipiente; combinacion; kit; metodo de preparacion; uso para tratar la diabetes.
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
CL2012001233A1 (es) Composicion farmaceutica liquida que comprende 0,01-1,5 mg/ml de un agonista de glp-1 que es despro36 exendida-4 (1-39)-lys6-nh2 o una sal, metionina y opcionalmente al menos un excipiente, libre de histidina; metodo de preparacion; uso para tratar la diabetes.
AR112480A1 (es) Composiciones de glp-1 y sus usos
MX2022008130A (es) Derivado de insulina.
AR095114A1 (es) Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina
AR070276A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion.
ES2572267T3 (es) Composiciones de insulina de acción súper rápida
AR110301A1 (es) Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
MX2015014007A (es) Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada.
CL2007002634A1 (es) Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
MX389091B (es) Tratamiento de pacientes con diabetes mellitus de tipo 2.
PE20191836A1 (es) Compuesto de insulina acilada
AR111341A1 (es) Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
BR112015003916A2 (pt) peptídeo selecionado a partir do grupo consistindo no peptídeo glp-1, no peptídeo gip e seus análogos resistentes a dipeptidil-peptidase iv (dpp-iv); e composição farmacêutica
RU2022119802A (ru) Композиции инсулинов длительного действия
AR102978A1 (es) Formulación de relación fija de insulina glargina / lixisenatida
CL2018002677A1 (es) Composición farmacéutica que comprende a) metformina, b) rosiglitazona o pioglitazona, c) sitagliptina, linagliptina o vildagliptina, y excipientes; y su uso para el tratamiento del desarrollo de ehna, sindrome de insulino-resistencia y la diabetes mellitus tipo 2, sop.
CL2015001962A1 (es) Kit que comprende un contenedor y una formulación estable que comprende una proteína heparan n-sulfatasa (hns) (divisional de solicitud 3653-12)

Legal Events

Date Code Title Description
FB Suspension of granting procedure